目的：探究驱动蛋白-13家族2C（KIF2C）对肝细胞癌（HCC）细胞增殖、侵袭和迁移以及人脐静脉内皮细胞（HUVEC）血管生成的影响，为HCC治疗提供潜在靶点。方法：用数据库数据分析KIF2C mRNA和蛋白在HCC组织中的表达及其与血管生成相关因子（VEGFR2 和HIF-1α）表达的相关性，常规培养人正常肝细胞QSG-7701、HUVEC 和HCC细胞Huh-7、Hep3B2.1-7，用 Lipofectamine 3000 转染试剂将 sh-NC 和 sh-KIF2C 转染至 Huh-7、Hep3B2.1-7 细胞，qPCR 检测各组 QSG-7701、Huh-7 和Hep3B2.1-7 细胞中KIF2C mRNA 的表达，WB 法检测各组细胞中KIF2C 蛋白的表达，细胞克隆形成实验检测敲低KIF2C 对Hep3B2.1-7 和Huh-7 细胞克隆形成的影响，小管生成实验检测敲低KIF2C 表达的Huh-7 和Hep3B2.1-7 细胞的条件培养液对HUVEC 血管生成能力的影响。结果：数据库分析结果显示，KIF2C mRNA 和蛋白在HCC 组织中均呈高表达（均P<0.01），用qPCR 和WB法检测人HCC中KIF2C mRNA和蛋白的表达水平，结果显示其mRNA和蛋白在各HCC 细胞中也呈高表达（均P<0.01），与数据库数据分析结果相符。数据库数据分析还显示，KIF2C 与HCC组织中VEGFR2、HIF-1α的表达水平呈正相关（P<0.05 或P<0.01）。成功构建了稳定低表达KIF2C 的Huh-7 和Hep3B2.1-7 细胞（均P<0.01），敲低KIF2C 表达均可明显抑制Huh-7和Hep3B2.1-7细胞的增殖能力（均P<0.01）、侵袭和迁移能力（均P<0.01），敲低KIF2C表达的HCC细胞条件培养液均可显著抑制体外HUVEC的血管生成能力（P<0.05 或P<0.01）。结论：KIF2C可促进Huh-7和Hep3B2.1-7细胞增殖、侵袭和迁移以及HUVEC血管生成的能力，提示KIF2C可能是治疗HCC的潜在靶点

Objective: To explore the effects of kinesin-13 family member 2C (KIF2C) on hepatocellular carcinoma (HCC) cell proliferation, invasion and migration as well as human umbilical vein endothelial cell (HUVEC) angiogenesis to provide potential targets for HCC treatment. Methods: Database data were used to analyze the expression of KIF2C mRNA and protein in HCC tissues and its correlation with the expression of angiogenesis-associated factors (VEGFR2 and HIF-1α). Human normal hepatocytes QSG-7701, HUVEC, and HCC cells Huh-7 and Hep3B2.1-7 were routinely cultured, and sh-NC and sh KIF2C were transfected into Huh-7 and Hep3B2.1-7 cells with Lipofectamine 3000 transfection reagent. qPCR was performed to detect the expression of KIF2C mRNA in QSG-7701, Huh-7 and Hep3B2.1-7 cells of each group, and WB was performed to detect the expression of KIF2C protein in cells of each group, and the effect of KIF2C knockdown on the clone formation of Huh3B2.1-7 and Huh-7 cells was examined in the clonogenic assay. Tubulogenesis assay to detect the effect of conditioned cultures of knockdown KIF2C-expressing Huh-7 and Hep3B2.1-7 cells on the angiogenic capacity of HUVEC cells. Results: Database analysis showed that KIF2C mRNA and protein were highly expressed in HCC tissues (both P<0.01). In addition, database analysis suggested that KIF2C mRNA may also be highly expressed in HCC cells, and the results of KIF2C mRNA and protein expression detected by qPCR and WB showed that its mRNA and protein were highly expressed in HCC cells (both P<0.01) , consistent with the database data analysis. Database data analysis also showed that KIF2C was positively correlated with the expression levels of VEGFR2 and HIF-1α in HCC tissues (P<0.05 or P<0.01). Stable low KIF2C-expressing Huh-7 and Hep3B2.1-7 cells were successfully constructed (both P<0.01), and knockdown of KIF2C expression significantly inhibited the proliferative (all P<0.01), invasive and migratory (all P<0.01) capacities of Huh-7 and Hep3B2.1-7 cells, and the conditioned culture medium of HCC cells with knockdown of KIF2C expression could significantly inhibit the angiogenic capacity of HUVEC cells in vitro (P<0.05 or P<0.01). Conclusion: KIF2C promotes the ability of Huh-7 and Hep3B2.1-7 cells to proliferate, invade and migrate as well as HUVEC angiogenesis, suggesting that KIF2C may be a potential target for the treatment of HCC.

武汉大学中南医院科技创新培育基金（WJ2019H034/ZNPY2018067）